(MedPage Today) — At the American Diabetes Association annual meeting, results from the ACHIEVE-5 trial showed that adding oral orforglipron (Foundayo) to basal insulin significantly improved glycemic control, reduced body weight, and limited…
Source link : https://www.medpagetoday.com/meetingcoverage/adavideopearls/122061
Author :
Publish date : 2026-07-06 16:45:00
Copyright for syndicated content belongs to the linked Source.
